Drug Profile


Alternative Names: ADI; ADI-PEG; ADI-PEG 20; ADI-SS PEG; Arginine deiminase pegylated; Arginine deiminase-PEG; Hepacid; Melanocid; PEG arginine deiminase; Peglyated arginine deiminase - Phoenix Pharmacologics; Pegylated arginine deiminase - Polaris Group

Latest Information Update: 07 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Phoenix Pharmacologics
  • Developer Barts and The London School of Medicine and Dentistry; Polaris Pharmaceuticals; University of Miami
  • Class Antineoplastics; Hydrolases; Polyethylene glycols; Proteins; Radiosensitisers
  • Mechanism of Action Arginine deiminase replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Mesothelioma; Hepatocellular carcinoma; Malignant melanoma
  • New Molecular Entity No

Highest Development Phases

  • Phase III Hepatocellular carcinoma
  • Phase II/III Mesothelioma
  • Phase II Acute myeloid leukaemia; Malignant melanoma; Non-Hodgkin's lymphoma; Small cell lung cancer
  • Phase I Breast cancer; Cancer; Gastrointestinal cancer; Non-small cell lung cancer; Pancreatic cancer; Prostate cancer; Solid tumours
  • Preclinical Bladder cancer; Glioblastoma; Lymphoma; Renal cell carcinoma; Sarcoma; Viral infections

Most Recent Events

  • 14 Jul 2017 Phase-I clinical trials in Solid tumours (Combination therapy, Late-stage disease, Second-line therapy or greater) in Taiwan (Parenteral) (NCT03254732)
  • 02 Jun 2017 Efficacy and adverse events data from the phase I TRAP trial in Mesothelioma presented at the 53rd Annual Meeting of the American Society of Clinical Oncology (ASCO-2017)
  • 10 May 2017 Polaris terminates a phase II trial for Small cell lung cancer (Second-line therapy or greater) in USA, Belgium, Germany, Taiwan and United Kingdom due to lack of efficacy in Cohort 2 and slow enrolment in Cohort 1 (IM) (NCT01266018)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top